NO803304L - Fremgangsmaate for fremstilling av et enzymderivat - Google Patents

Fremgangsmaate for fremstilling av et enzymderivat

Info

Publication number
NO803304L
NO803304L NO803304A NO803304A NO803304L NO 803304 L NO803304 L NO 803304L NO 803304 A NO803304 A NO 803304A NO 803304 A NO803304 A NO 803304A NO 803304 L NO803304 L NO 803304L
Authority
NO
Norway
Prior art keywords
procedure
preparation
enzyme derivative
enzyme
derivative
Prior art date
Application number
NO803304A
Other languages
English (en)
Other versions
NO163867C (no
NO163867B (no
Inventor
Richard Anthony Godwin Smith
John Gordon Winchester
Original Assignee
Beecham Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Ltd filed Critical Beecham Group Ltd
Publication of NO803304L publication Critical patent/NO803304L/no
Publication of NO163867B publication Critical patent/NO163867B/no
Publication of NO163867C publication Critical patent/NO163867C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3153Streptokinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99Enzyme inactivation by chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO803304A 1979-11-05 1980-11-04 Fremgangsmaate for fremstilling av et enzymderivat. NO163867C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7938279 1979-11-05

Publications (3)

Publication Number Publication Date
NO803304L true NO803304L (no) 1981-05-06
NO163867B NO163867B (no) 1990-04-23
NO163867C NO163867C (no) 1990-08-01

Family

ID=10508982

Family Applications (1)

Application Number Title Priority Date Filing Date
NO803304A NO163867C (no) 1979-11-05 1980-11-04 Fremgangsmaate for fremstilling av et enzymderivat.

Country Status (18)

Country Link
US (1) US4808405A (no)
EP (1) EP0028489B1 (no)
JP (1) JPS5678590A (no)
AR (1) AR224786A1 (no)
CA (1) CA1174621A (no)
CS (2) CS391991A3 (no)
DE (1) DE3065190D1 (no)
DK (1) DK158994C (no)
ES (1) ES8204467A1 (no)
GR (1) GR72121B (no)
HK (1) HK65886A (no)
HU (1) HU185223B (no)
IE (1) IE50174B1 (no)
IL (1) IL61408A (no)
NL (1) NL930029I2 (no)
NO (1) NO163867C (no)
NZ (1) NZ195469A (no)
ZA (1) ZA806641B (no)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3361610D1 (en) * 1982-04-07 1986-02-06 Beecham Group Plc Enzyme derivatives, process for preparing them and pharmaceutical compositions containing them
EP0125269A1 (en) * 1982-11-11 1984-11-21 Beecham Group Plc Pharmaceutically active compounds
GB8400653D0 (en) * 1984-01-11 1984-02-15 Beecham Group Plc Conjugates
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US5231006A (en) * 1986-10-16 1993-07-27 Behringwerke Aktiengesellschaft Method for the determination of plasminogen
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
JPH0296536A (ja) * 1988-09-29 1990-04-09 Green Cross Corp:The プラスミノゲン乾燥製剤
WO1990013640A1 (en) * 1989-05-01 1990-11-15 The University Of Notre Dame Du Lac Methods and materials for expression of human plasminogen in a eukaryotic cell system
EP0397366A1 (en) * 1989-05-09 1990-11-14 The Board Of Regents Of The University Of Oklahoma Hybrid streptokinases with fibrin binding domains and methods for the synthesis of same
JPH05501855A (ja) * 1989-05-17 1993-04-08 リサーチ、コーポレーション、テクノロジーズ、インコーポレーテッド 哺乳動物における血栓症の治療に関する方法及び組成物
CA2027936C (en) 1989-10-23 2001-07-24 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5190756A (en) * 1989-12-01 1993-03-02 Genentech, Inc. Methods and materials for expression of human plasminogen variant
US5087572A (en) * 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
GB8928163D0 (en) * 1989-12-13 1990-02-14 Beecham Group Plc Novel treatment
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
US5187069A (en) * 1990-08-06 1993-02-16 Henry Ford Health System Active site labelling of plasminogen
AU1873092A (en) * 1991-04-09 1992-11-17 Brigham And Women's Hospital Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques
US5520912A (en) * 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
US6004955A (en) * 1996-08-15 1999-12-21 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as IIb/IIIa antagonists
PL337831A1 (en) 1997-06-19 2000-09-11 Du Pont Pharm Co Inhibitors of factor xa containing a specificity giving p1 group
EP1203026A4 (en) * 1999-07-29 2005-03-16 Dyax Corp FRACTIONS BINDING FIBRIN
US6388073B1 (en) 2000-07-26 2002-05-14 Shire Us Inc. Method for the manufacture of anagrelide
KR20010000669A (ko) * 2000-10-12 2001-01-05 김기환 스트렙토키나제와 사람 혈청알부민의 포합체를유효성분으로 함유하는 전신투여용 지속성 혈전 용해제
US6984373B2 (en) * 2000-12-23 2006-01-10 Dyax Corp. Fibrin binding moieties useful as imaging agents
CN104744461A (zh) 2001-09-21 2015-07-01 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20060030574A1 (en) * 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
US7700608B2 (en) * 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
CN101137412B (zh) 2005-01-13 2012-11-07 布里斯托尔-迈尔斯·斯奎布公司 用作凝血因子XIa抑制剂的取代的二芳基化合物
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
EP1896466B1 (en) 2005-06-27 2011-04-13 Bristol-Myers Squibb Company N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007002584A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
EP1899299B1 (en) 2005-06-27 2010-10-20 Bristol-Myers Squibb Company C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2007002634A1 (en) 2005-06-27 2007-01-04 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
JP2009539873A (ja) 2006-06-08 2009-11-19 ブリストル−マイヤーズ スクイブ カンパニー 抗凝固剤として有用な第VIIa因子インヒビターとしての2−アミノカルボニルフェニルアミノ−2−フェニルアセトアミド類
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7910597B2 (en) * 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US8410155B2 (en) 2006-12-15 2013-04-02 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
WO2008157162A1 (en) 2007-06-13 2008-12-24 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
AR071823A1 (es) 2008-05-19 2010-07-14 Schering Corp Derivados heterociclicos de imidazol y pirazol, inhibidores del factor ixa de coagulacion, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diversos trastornos tromboembolicos.
AU2010260208B2 (en) 2009-06-16 2014-11-13 Bristol-Myers Squibb Holdings Ireland Unlimited Company Dosage forms of apixaban
EP2462123B1 (en) 2009-08-04 2013-10-02 Merck Sharp & Dohme Corp. 4,5,6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
CA2789622C (en) 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子xia抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為xia因子抑制劑之環狀p1接合劑
SG11201401384UA (en) 2011-10-14 2014-09-26 Bristol Myers Squibb Co Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9079929B2 (en) 2011-10-14 2015-07-14 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
US9108951B2 (en) 2011-10-14 2015-08-18 Bristol-Myers Squibb Company Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors
WO2013068875A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. 2-thiopyrimidinones
AU2013245353A1 (en) 2012-04-06 2014-09-25 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
KR20150038369A (ko) 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
WO2014022767A1 (en) 2012-08-03 2014-02-06 Bristol-Myers Squibb Company Dihydropyridone p1 as factor xia inhibitors
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
EP3055300B1 (en) 2013-10-09 2018-03-07 Pfizer Inc Antagonists of prostaglandin ep3 receptor
IL307212A (en) 2014-01-31 2023-11-01 Bristol Myers Squibb Co Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors
NO2760821T3 (no) 2014-01-31 2018-03-10
AU2015233094B2 (en) 2014-03-17 2017-04-27 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
ES2910128T3 (es) 2014-04-04 2022-05-11 Pfizer Compuestos de heteroarilo o arilo fusionados con biciclo y su uso como inhibidores de IRAK4
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
NO2721243T3 (no) 2014-10-01 2018-10-20
CR20170498A (es) 2015-05-05 2018-01-26 Pfizer 2-tiopirimidinonas
CA2989456C (en) 2015-06-17 2022-01-04 Pfizer Inc. Tricyclic compounds and their use as phosphodiesterase inhibitors
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
CN114805365B (zh) 2015-07-29 2024-07-23 百时美施贵宝公司 携带非芳族p2′基团的因子xia新大环
JP6785838B2 (ja) 2015-08-05 2020-11-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 新規な置換グリシン誘導のfxia阻害剤
DK3341367T3 (da) 2015-08-27 2021-04-12 Pfizer Bicyklisk-fusionerede heteroaryl- eller arylforbindelser som irak4-modulatorer
JP2019507167A (ja) 2016-03-02 2019-03-14 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 第xia因子阻害活性を有するジアミド大員環
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
AU2019329884B2 (en) 2018-08-31 2022-01-27 Pfizer Inc. Combinations for treatment of NASH/NAFLD and related diseases
US20220387402A1 (en) 2019-05-20 2022-12-08 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
US20230312560A1 (en) 2020-07-22 2023-10-05 Janssen Pharmaceutica Nv Compounds useful as factor xia inhibitors
WO2023026180A1 (en) 2021-08-26 2023-03-02 Pfizer Inc. Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178368A (en) * 1971-09-30 1979-12-11 Behringwerke Aktiengesellschaft Method for the treatment of thromboembolism
JPS5325775A (en) * 1976-08-24 1978-03-09 Miller Fluid Power Corp Module type fluid flow control element
US4082612A (en) * 1976-09-24 1978-04-04 Michael Reese Research Foundation Plasminogen activator complex
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions

Also Published As

Publication number Publication date
CS391991A3 (en) 1992-06-17
NZ195469A (en) 1984-05-31
AU534017B2 (en) 1983-12-22
IL61408A0 (en) 1980-12-31
IE50174B1 (en) 1986-02-19
CS391191A3 (en) 1992-08-12
NL930029I2 (nl) 1993-12-01
IE802277L (en) 1981-05-05
IL61408A (en) 1983-10-31
EP0028489A1 (en) 1981-05-13
HK65886A (en) 1986-09-12
GR72121B (no) 1983-09-16
US4808405A (en) 1989-02-28
JPH0316114B2 (no) 1991-03-04
NO163867C (no) 1990-08-01
JPS5678590A (en) 1981-06-27
DE3065190D1 (en) 1983-11-10
NO163867B (no) 1990-04-23
DK158994B (da) 1990-08-13
NL930029I1 (nl) 1993-06-01
EP0028489B1 (en) 1983-10-05
ES496586A0 (es) 1982-05-01
AR224786A1 (es) 1982-01-15
ES8204467A1 (es) 1982-05-01
CA1174621A (en) 1984-09-18
AU6401180A (en) 1981-05-14
HU185223B (en) 1984-12-28
ZA806641B (en) 1981-10-28
DK468880A (da) 1981-05-06
DK158994C (da) 1991-01-07

Similar Documents

Publication Publication Date Title
NO803304L (no) Fremgangsmaate for fremstilling av et enzymderivat
DK373479A (da) Fremgangsmaade til fremstilling af et enzymderivat
NO790358L (no) Fremgangsmaate for fremstilling av alkylendiaminderivater
NO811731L (no) Fremgangsmaate for fremstilling av imidazo-rifamycin-derivater
NO813678L (no) Fremgangsmaate for fremstilling av karbostyrilderivater
NO800830L (no) Fremgangsmaate ved fremstilling av glycinamidderivater
NO802913L (no) Fremgangsmaate ved fremstilling av cephalosporinforbindelse
NO791831L (no) Fremgangsmaate for fremstilling av aminotiazoler
NO151269C (no) Fremgangsmaate for fremstilling av fiskemel
NO792404L (no) Fremgangsmaate for fremstilling av imidazolderivater
NO151895C (no) Fremgangsmaate for fremstilling av pyrido-indolderivater
NO802196L (no) Fremgangsmaate for fremstilling av diester-diamider
AR222691A1 (es) Procedimiento de preparacion de derivados hidroxi-de 2-isopropilamino-pirimidina
NO150799C (no) Fremgangsmaate for fremstilling av lysergol-derivater
NO813477L (no) Fremgangsmaate for fremstilling av karbostyrilderivater
NO801982L (no) Fremgangsmaate ved fremstilling av svovelholdige isokinolinderivater
NO802435L (no) Fremgangsmaate til fremstilling av tetrahydrokinolinderivater
NO793103L (no) Fremgangsmaate til fremstilling av cefalosporinderivater
NO152254C (no) Fremgangsmaate til fremstilling av karbazolderivater
NO812842L (no) Fremgangsmaate for fremstilling av aminoacetonitil-derivater
NO792659L (no) Fremgangsmaate for fremstilling av karbostyrilderivater
NO801234L (no) Fremgangsmaate for fremstilling av isopropylaminopyrimidin-hydroksyderivater
NO801724L (no) Fremgangsmaate for fremstilling av ergopeptin-derivater
NO800564L (no) Fremgangsmaate for fremstilling av penicillinderivater
NO149774C (no) Fremgangsmaate for fremstilling av et azetidinon